Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zolasartan SCHEMBL30735999 | 0.88 | AGTR1 (0.78) | AGTR1AGTR2 | |
| Zolasartan SCHEMBL489476 | 0.88 | AGTR1 (0.78) | AGTR1AGTR2 | |
| Zolasartan SCHEMBL27347758 | 0.87 | AGTR1 (0.77) | AGTR1AGTR2 | |
| Zolasartan SCHEMBL9311614 | 0.87 | AGTR1 (0.77) | AGTR1AGTR2 | |
| SCHEMBL9309106 | 0.87 | AGTR1 (0.77) | AGTR1AGTR2 | |
| SCHEMBL9859264 | 0.86 | AGTR1 (0.76) | AGTR1AGTR2 | |
| SCHEMBL9309852 | 0.85 | AGTR1 (0.74) | AGTR1AGTR2 | |
| SCHEMBL9309324 | 0.84 | AGTR1 (0.73) | AGTR1AGTR2 | |
| SCHEMBL9310803 | 0.84 | AGTR1 (0.72) | AGTR1AGTR2 | |
| Carboxylic Acid Metabolite SCHEMBL29699808 | 0.84 | AGTR1 (1.00) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299177-A1 | Risk Stratification of Patients with Chronic Myocardial Infarction | MALLINCKRODT INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299177-A1 | Risk Stratification of Patients with Chronic Myocardial Infarction | FABP3, TNNI3, TNNT2 | AGTR1 249/4885AGTR2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.